Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
Company plans to submit ONWARD results to both European and U.S. regulatory agencies.
AD04
Adial Pharmaceuticals Receives Notice of Allowance on the U.S. Patent for the Treatment for Opioid Use Disorder Using AD04
Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor.